Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: ahhaha who wrote (277)	8/3/1998 4:16:00 PM
From: Dr. Voodoo	Read Replies (1) \| Respond to of 399

That fishin' trip was great! >>>Do you know what lead optimization is? If it was all that simple don't you think that research would have been into all of this over the last 50 years? The only thing that has changed is the complexity of chemicals creatable now. More complexity undermines the potential of lead optimization. IMO, this is jibberish. In order to optimize a lead one makes a series of of compounds with given shapes, sizes, and electrostatic configurations similar to the lead. The more you can make, the more you can test, the closer to an ideal fit to target you can get. Once you're on the dance floor MUCH is known about the way those molecules will interact and how to make a better one. More complex gets you more information with which you can specifically knock out a relevant biological target. Over the last 50 years THOUSANDS of leads have been optimized. This is a primary principal of ME TOO drugs. Think of the hundreds if not THOUSANDS of beta lactams for instance. Or how about the most recent protease inhibitors. All of these have a structural similarity that is a small variation of the other. How did they get found? Next thing you're going to try to tell me is that we(scientists) really don't have any idea of the chemical structure of what we are making? No offense intended, but your previous statements have left me unimpressed with your understanding of drug discovery, structural biology and plain old fashioned SAR based Medicinal Chemistry. I still infer that you would rather see us in the stone age when it comes to developing drugs. Your market prowess while correct in the case of Arqule, does not rationally describe what has happened to much of the biotech sector, and small cap markets in general for that matter. I'll patiently wait till this dog hunts.